The Harbor Health Care ETF returned 15.30% in the second quarter of 2026, led by strong gains in biotechnology stocks fueled by clinical data and merger activity. Pharmaceutical stocks lagged due to the ETF's lower exposure to Eli Lilly, a major benchmark component. Looking ahead to Q3, the outlook for mergers and acquisitions in biopharma is even more positive, suggesting continued potential growth in this sector.
Eli Lilly (LLY) trades at USD 1,147.39 with a 1-day gain of 0.85% as of Sep 15, 2026 15:21 WIB on Pluang. The Harbor Health Care ETF's Q2 2026 return of 15.30% contrasts with its lower exposure to Eli Lilly, a major benchmark stock. This dynamic highlights the ETF's focus on biotechnology stocks, which drove its strong quarterly performance.
More than 200 companies are actively developing over 240 Alzheimer's disease therapies, with around 20 drugs in late-stage trials and many others in earlier phases. Key players include Eli Lilly, Biogen, Johnson & Johnson, and Eisai, focusing on inno...
Goldman Sachs has increased its price target for Eli Lilly stock to $1,413, signaling an 8.87% potential upside amid strong revenue growth in the competitive weight-loss drug market. Despite projected revenue rising 25.59% to $22.11 billion, earnings...
Eli Lilly's stock rose 4% following a positive recommendation from the European Medicines Agency for its oral obesity pill, Foundayo, which is now close to final approval in the EU. This pill offers dosing flexibility and treats both weight managemen...
Eli Lilly reported a strong 47.7% revenue growth last quarter, driven by its expanding weight-loss drug franchise including Mounjaro and Zepbound. Analysts project that a $1,000 investment in the company could grow to about $1,830 by 2031, reflecting...
Eli Lilly reported strong Q2 earnings with revenue up 47.67% and EPS beating estimates, driven by high sales of its obesity drug Mounjaro. The company raised its 2026 revenue guidance to $85-$87 billion and is optimistic about the upcoming U.S. filin...
